Potential of BGB-11417, a BCL2 inhibitor, in hematological malignancies
- PMID: 38264792
- DOI: 10.1080/13543784.2024.2309873
Potential of BGB-11417, a BCL2 inhibitor, in hematological malignancies
Erratum in
-
Correction.Expert Opin Investig Drugs. 2024 Feb;33(2):159. doi: 10.1080/13543784.2024.2319956. Epub 2024 Feb 19. Expert Opin Investig Drugs. 2024. PMID: 38372200 No abstract available.
Keywords: BCL2 inhibitors; BGB-11417; Sonrotoclax; lymphoid malignancies; myeloid malignancies.